×
About 643 results

ALLMedicine™ Primary CNS Lymphoma Center

Research & Reviews  230 results

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02203526

Nov 22nd, 2021 - Background: Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included hi...

Chronic inflammatory demyelinating polyneuropathy evolving to primary CNS lymphoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565527
BMJ Case Reports; Kajtazi NI, Khalid E et. al.

Nov 4th, 2021 - A 56-year-old woman presented with 3 months history of all four limbs' numbness in glove and stocking distribution. A week before admission, she developed all four limbs' weakness and numbness. Brain and whole spine imaging revealed no lesions, an...

Primary CNS Lymphoma: Comparison of Outcomes and the Use of Radiation Therapy in Patien...
https://doi.org/10.1016/j.ijrobp.2021.07.1072
International Journal of Radiation Oncology, Biology, Phy... Patel AM, Ali O et. al.

Oct 28th, 2021 - The role of whole-brain radiation therapy (WBRT) in primary CNS lymphoma (PCNSL) has changed over time and current practices vary by institution and resource availability. This study compares the treatment patterns and outcomes among PCNSL patient...

Implications of recent molecular achievements in early diagnosis and precision treatmen...
https://doi.org/10.1080/14728222.2021.1988927
Expert Opinion on Therapeutic Targets; Calimeri T, Steffanoni S et. al.

Oct 5th, 2021 - Introduction: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) represents a relevant challenge in onco-hematology. PCNSL has specific molecular profile and biological characteristics that distinguish it from syst...

Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lympho...
https://doi.org/10.1212/WNL.0000000000012515
Neurology Houillier C, Chabrot CM et. al.

Sep 29th, 2021 - To evaluate the efficacy and tolerance of the association rituximab-lenalidomide-ibrutinib (R2I) in relapsed/refractory (R/R) primary CNS lymphoma (PCNSL). R/R PCNSL patients treated with R2I were retrospectively selected and analyzed from the Fre...

see more →

Clinicaltrials.gov  18 results

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02203526

Nov 22nd, 2021 - Background: Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included hi...

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
https://clinicaltrials.gov/ct2/show/NCT03964090

Sep 8th, 2021 - Background: Aggressive B-cell lymphomas with secondary involvement of the CNS (sCNSL) have a grave prognosis No standard of care exists for sCNSL; treatment approaches include combination chemotherapy regimens effective in primary CNS lymphoma (PC...

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05021770

Aug 26th, 2021 - The purpose of this study was to investigate the maximum tolerated dose and efficacy of Orelabrutinib combined with Thiotepa in refractory and relapsed primary central nervous system lymphoma (PCNSL).

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04656431

Aug 19th, 2021 - PRIMARY OBJECTIVES To determine the safety and tolerability of hyperpolarized 13C MR metabolic imaging as a new and unique tool in the evaluation of tumor burden and detecting early response to standard therapy in participants with PCNSL. To asses...

De-escalated Induction Treatment in Primary CNS Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04931368

Jun 22nd, 2021 - This phase III study investigates if a de-escalated induction treatment in newly diagnosed primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free survival. Two arms are compared, in the experimental treatment group...

see more →

News  9 results

Blood-Brain-Barrier Therapy for CNS Tumors May Have Lasting Effect on Vision
https://www.medscape.com/viewarticle/942415

Dec 16th, 2020 - NEW YORK (Reuters Health) - Osmotic blood-brain-barrier disruption (BBBD) therapy, which increases the penetration of chemotherapeutics into malignant tumors of the central nervous system (CNS), may also affect sight, researchers say. "Osmotic blo...

Assessing Pathologic Evaluation in Patients with DLBCL Within the Veterans Health Administration
https://www.mdedge.com/fedprac/article/227808/oncology/assessing-pathologic-evaluation-patients-dlbcl-within-veterans
Ryan A. Williams, MD, Madison H. Williams, MD et. al.

Sep 1st, 2020 - INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Patients with DLBCL refractory to initial treatment or who experience relapse have low rates of prolonged disease-free survival.

Review of Radiologic Considerations in an Immunocompetent Patient With Primary Central Nervous System Lymphoma
https://www.mdedge.com/fedprac/avaho/article/206078/lymphoma-plasma-cell-disorders/review-radiologic-considerations
Bosten Miller, MD, Igor Sirotkin, MD et. al.

Aug 7th, 2019 - Central nervous system (CNS) lymphoma can be classified into 2 categories: primary CNS lymphoma (PCNSL), which includes disease limited to brain, eyes, spinal cord; and leptomeninges without coexisting or previous systemic lymphoma. Secondary CNS.

Rituximab boosts survival in primary CNS lymphoma
https://www.mdedge.com/hematology-oncology/article/197142/b-cell-lymphoma/rituximab-boosts-survival-primary-cns-lymphoma?channel=59374
Will Pass

Mar 22nd, 2019 - For patients with primary central nervous system lymphoma (PCNSL), adding rituximab to combination high-dose methotrexate and temozolomide significantly boosted the 5-year overall survival rate, according to a retrospective study. The triplet comb.

Rituximab boosts survival in primary CNS lymphoma
https://www.mdedge.com/hematology-oncology/article/197142/b-cell-lymphoma/rituximab-boosts-survival-primary-cns-lymphoma
Will Pass

Mar 22nd, 2019 - For patients with primary central nervous system lymphoma (PCNSL), adding rituximab to combination high-dose methotrexate and temozolomide significantly boosted the 5-year overall survival rate, according to a retrospective study. The triplet comb.

see more →